γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of established tumors, combined with increased survival and reduced cancer-associated bone disease. Pretreatment with ZOL, a U.S. Food and Drug Administration–approved bisphosphonate prescribed to mitigate pathological fracture in mCRPC patients, resulted in CAR-independent activation of γδ CAR-T cells, increased cytokine secretion, and enhanced antitumor efficacy. These data show that the activity of the endogenous Vγ9Vδ2 T cell receptor is preserved in CAR-T cells, allowing for dual-receptor recognition of tumor cells. Collectively, our findings support the use of γδ CAR-T cell therapy for mCRPC treatment.

[1]  D. Abate-Daga,et al.  Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities , 2022, Science Immunology.

[2]  A. Regev,et al.  CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours , 2022, Nature.

[3]  F. Bushman,et al.  PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial , 2022, Nature Medicine.

[4]  A. Landin,et al.  Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product. , 2021, Journal of visualized experiments : JoVE.

[5]  Leah M. Cook,et al.  Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer , 2021, Nature Communications.

[6]  S. Hacein-Bey-Abina,et al.  Engineering Next-Generation CAR-T Cells for Better Toxicity Management , 2020, International journal of molecular sciences.

[7]  M. Rubin,et al.  A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance , 2020, Nature Cancer.

[8]  M. Bar,et al.  Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies. , 2020, Blood.

[9]  S. Gottschalk,et al.  CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Kabelitz,et al.  Cancer immunotherapy with γδ T cells: many paths ahead of us , 2020, Cellular & Molecular Immunology.

[11]  J. Schachter,et al.  Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia , 2020, Frontiers in Immunology.

[12]  R. Bergmann,et al.  Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy , 2020, Oncoimmunology.

[13]  W. Han,et al.  Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy , 2019, Journal of Hematology & Oncology.

[14]  D. Abate-Daga,et al.  CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms , 2019, BioDrugs.

[15]  I. Prinz,et al.  Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies , 2019, Nature Reviews Drug Discovery.

[16]  J. Cleveland,et al.  Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis , 2019, Oncogene.

[17]  U. Rix,et al.  An immunoproteomic approach to characterize the CAR interactome and signalosome , 2019, Science Signaling.

[18]  S. Perez,et al.  Prostate cancer: any room left for immunotherapies? , 2019, Immunotherapy.

[19]  T. Lahusen,et al.  Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local , 2018, Front. Immunol..

[20]  A. Wu,et al.  Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer , 2017, Oncoimmunology.

[21]  H. Abken,et al.  CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. , 2017, Human gene therapy.

[22]  R. Junghans,et al.  Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response , 2016, The Prostate.

[23]  David Basanta,et al.  Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer , 2016, Scientific Reports.

[24]  K. Pienta,et al.  Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation , 2016, Journal of visualized experiments : JoVE.

[25]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[26]  S. Chiplunkar,et al.  Activation status of γδ T cells dictates their effect on osteoclast generation and bone resorption , 2015, Bone reports.

[27]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[28]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[29]  F. Locatelli,et al.  gd T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR- ab 1 /CD19 1 lymphocytes , 2016 .

[30]  C. Harly,et al.  Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human Vγ9Vδ2 T Cells , 2014, Front. Immunol..

[31]  D. Basanta,et al.  Current and emerging therapies for bone metastatic castration-resistant prostate cancer. , 2015, Cancer control : journal of the Moffitt Cancer Center.

[32]  L. Cooper,et al.  Clinical Applications of Gamma Delta T Cells with Multivalent Immunity , 2014, Front. Immunol..

[33]  R. Morgan,et al.  Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins. , 2014, Nucleic acid therapeutics.

[34]  W. Burns,et al.  A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. , 2014, Human gene therapy.

[35]  S. Rosenberg,et al.  Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. , 2013, Blood.

[36]  M. Cilli,et al.  Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[38]  P. Vantourout,et al.  Six-of-the-best: unique contributions of γδ T cells to immunology , 2013, Nature Reviews Immunology.

[39]  I. Măndoiu,et al.  Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. , 2012, Journal of immunological methods.

[40]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[41]  K. Kakimi,et al.  Expansion of human peripheral blood γδ T cells using zoledronate. , 2011, Journal of visualized experiments : JoVE.

[42]  J. Mönkkönen,et al.  Biochemical and molecular mechanisms of action of bisphosphonates. , 2011, Bone.

[43]  P. Clézardin.  Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. , 2011, Bone.

[44]  Thomas E. Moritz,et al.  The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. , 2010, Urology.

[45]  I. Holen,et al.  Anti-tumour effects of bisphosphonates--what have we learned from in vivo models? , 2009, Current cancer drug targets.

[46]  J. Mönkkönen,et al.  Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP , 2009, British journal of haematology.

[47]  C. Agrati,et al.  In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients , 2008, Cancer Immunology and Immunotherapy.

[48]  J. Nelson,et al.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[49]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[50]  Wancai Yang,et al.  γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity , 2003, The Journal of experimental medicine.

[51]  F. Singer,et al.  Bisphosphonate treatment inhibits the growth of prostate cancer cells. , 2001, Cancer research.

[52]  M. Groettrup,et al.  Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. , 2000, Cancer research.

[53]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[54]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[55]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .